We are pleased to announce the sale of our client, Design Space InPharmatics, LLC, to ProductLife Group. The acquisition closed April 23, 2021.

Located in Harleysville, Pennsylvania, Design Space InPharmatics (DSI) offers one-stop, full-service regulatory and CMC consulting to pharmaceutical and biopharmaceutical companies, leveraging multidisciplinary teams comprised of close to 50 manufacturing, quality, and regulatory affairs experts.

DSI consultants bring decades of experience to every stage of the regulatory and product development process, from initial selection of development and manufacturing sources, design and evaluation of the investigational manufacturing process through the scale-up for commercialization to and through approval.

Over the last ten years, the Company has contributed to more than 60 original INDs, 25 NDAs/BLAs and produced materials for more than 50 interactions with the European and U.S. agencies.

Headquartered in Paris, France, ProductLife Group’s (PLG) mission is to improve human health by delivering regulatory compliance services for the safe and effective use of medical solutions. For almost 30 years, PLG has supported clients through the entire product lifecycle, combining local expertise with global reach spanning more than 110 countries.

PLG provides consulting and outsourcing services in the areas of regulatory affairs, quality and compliance, vigilance and medical information, covering both established products and innovative therapeutics & diagnostics.

With a goal of continuously improving the value delivered to people and customers, PLG is committed to long-term partnerships, innovation, flexibility, and cost-efficiency.

The strategic acquisition of DSI, which further strengthens PLG’s biopharma capability and provides a strong foothold in North America, is the next step in PLG’s global expansion plan.

This new alliance will pave the way for further acceleration of the two companies’ growth plans by allowing clients to benefit from additional expertise, as well as from PLG’s extensive geographic reach.

“I’ve been very impressed by DSI. Their experts all have decades of practical industry and agencies interaction experience, providing an unparalleled perspective on how to navigate new product development in a complex and evolving regulatory environment, and ultimately arrive at market in the most efficient way,” commented Xavier Duburcq, PLG CEO.

“We will leverage this experience to support our clients in their global efforts to accelerate the path to approval and to implement compliant drug development strategies.”

“Together PLG and DSI will be able to support clients in all stages of the product lifecycle, from pre-clinical work to post-approval compliance, through the review and approval processes and market-entry strategy. This is a very exciting step for us all,” Duburcq added.

Commenting on the merger with PLG, Edward Narke and Anthony Durning, co-founders at DSI, and Brian Lihou, newly appointed General Manager of DSI, said, “We could not be more pleased to become part of a global leader in the life sciences regulatory and compliance industry.”

“Joining PLG is exciting, both for DSI as a business, as well as for our clients, which will now have access to additional specialist expertise and international coverage spanning more than 100 countries.”

Generational Equity Executive Managing Director, M&A-Technology Practice Leader, David Fergusson, and his team, led by Managing Director, M&A, Moses Shmueli, with the support of Vice President, Mergers & Acquisitions, Tristan Keeffe, successfully closed the deal. Senior Managing Director Ashok Tandon established the initial relationship with DSI.

“The success of DSI was led by Edward Narke and Anthony Durning, two exceptional entrepreneurs, who envisioned and executed very thoughtfully to build such a valuable company,” said Shmueli.

“With PLG as a partner, I expect to see DSI continue to grow and I look forward to following the continued achievements of the combined entities.”